Hexagon Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Hexagon Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$12.8K	–	828
2025 Q1	$12.8K	Sell	100 -307	-75%	-$41.6K	﹤0.01%	894
2024 Q4	$53.8K	Buy	407 +307	+307%	+$43.2K	0.01%	455
2024 Q3	$14.6K	Hold	100	–	–	﹤0.01%	811
2024 Q2	$13.7K	Hold	100	–	–	﹤0.01%	788
2024 Q1	$13.7K	Hold	100	–	–	﹤0.01%	769
2023 Q4	$13.6K	Hold	100	–	–	﹤0.01%	755
2023 Q3	$12.2K	Hold	100	–	–	﹤0.01%	689
2023 Q2	$12.7K	Hold	100	–	–	﹤0.01%	683
2023 Q1	$12.9K	Hold	100	–	–	﹤0.01%	670
2022 Q4	$13.1K	Hold	100	–	–	﹤0.01%	657
2022 Q3	$12K	Hold	100	–	–	﹤0.01%	721
2022 Q2	$12K	Buy	+100	New	+$11.9K	﹤0.01%	623

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Hexagon Capital Partners's IBB Position: Q2 2025 in Review

Hexagon Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2025, closing a stake of 100 shares — an estimated $12.8K sold.

Hexagon Capital Partners first reported a position in IBB in Q2 2022 and held it in 12 quarters. The position peaked at $53.8K in Q4 2024. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.

Hexagon Capital Partners reported no remaining iShares Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 100 iShares Biotechnology ETF shares in Q2 2025, an estimated $12.8K.
Hexagon Capital Partners first reported a position in iShares Biotechnology ETF in Q2 2022 and held it in 12 quarters.
Hexagon Capital Partners's iShares Biotechnology ETF position peaked at $53.8K in Q4 2024.
797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.